Amolyt Pharma

About Us

We are building and advancing a portfolio through global approval by establishing strong ties and collaborations with endocrinologists, the medical community at large and patient advocacy organizations worldwide.

Our goal is to provide physicians with new therapeutic strategies to improve the lives of their patients with rare endocrine and related diseases. Currently, our development pipeline includes two therapeutic peptide programs: AZP-3601 for the treatment of hypoparathyroidism and AZP-3813 for the treatment of acromegaly. Simultaneously, we continue to build our pipeline and have an on-going research program for a novel therapeutic peptide candidate, AZP-3404. We also continuously look for external innovation in rare endocrine and related diseases.

Our global management team is composed of a highly dedicated group of senior executives with proven drug development, registration and commercialization, and achievements in peptide therapeutics, as well as thorough knowledge of rare endocrine and related disease.

We are supported by an impressive board of directors and strong international syndicate of investors, as well as a robust IP portfolio and key academic collaborations.

LEADERSHIP

Management

Our global management team is composed of a highly dedicated group of senior executives with proven drug development expertise and achievements in peptide therapeutics, as well as thorough knowledge of rare endocrine and metabolic disorders.

Thiery Abribat
Thierry Abribat, Ph.D.

Founder and Chief Executive Officer

Thierry Abribat, Ph.D.

Founder and Chief Executive Officer

Thierry Abribat is a biotech entrepreneur who has founded and managed three biotech companies, one of which, Alizé Pharma 2, was acquired by Jazz Pharmaceuticals (Nasdaq: JAZZ) and, another, Alizé Pharma, was acquired by Millendo Therapeutics (Nasdaq: MLND). Prior to founding Alizé Pharma, he held several executive positions with increasing responsibilities in drug development, business development and management at Theratechnologies (TSX: TH) and at OPi, Pharmaceuticals for Rare Diseases, until OPi’s acquisition by EUSA Pharma Inc. Thierry began his career as a scientist for Sanofi, then at University of Montreal and as a consultant to the biopharmaceutical industry. He holds a Doctorate of Veterinary Medicine and a Ph.D. from the National Polytechnic Institute of Toulouse.

Louis J. Arcudi III

Chief Financial Officer

Louis J. Arcudi III

Chief Financial Officer

Louis J. Arcudi III currently serves as Amolyt Pharma’s chief financial officer. Mr. Arcudi joined Amolyt from Millendo Therapeutics, where he served as chief executive officer since February 2021, and chief financial officer prior to that. Prior to joining Millendo, Mr. Arcudi served as senior vice president of operations and chief financial officer at Idera Pharmaceuticals. Before that, he served as vice president of finance and administration for Peptimmune, Inc. where he handled all financial business and operations. Before his time at Peptimmune, Mr. Arcudi served as senior director of finance and administration at Genzyme Molecular Oncology Corporation, after serving as director of international finance and commercial operations at Genzyme Corporation. Earlier in his career, he held finance positions with increasing levels of responsibility at Cognex Corporation, Millipore Corporation and General Motors Corporation. Mr. Arcudi obtained his MBA from Bryant College and B.S. in accounting and information systems from the University of Southern New Hampshire.

Michael Culler
Michael Culler, Ph.D.

Chief Scientific Officer

Michael Culler, Ph.D.

Chief Scientific Officer

Michael Culler brings over 35 years of research experience and is an internationally recognized expert in endocrinology, metabolic disorders and peptide therapeutics with over 200 publications and 22 patents. He was formerly vice president of endocrinology research for Ipsen, where he led programs in diverse endocrine/metabolic areas that resulted in six compounds reaching clinical development. Michael led the preclinical programs that produced the key assets for Rhythm Pharmaceuticals (relamorelin and setmelanotide), Tiburio Therapeutics (TBR-760 and 065), and Radius Pharma (abaloparatide; Tymlos®). He is a co-founder of Rhythm Pharmaceuticals and the scientific founder of Tiburio Therapeutics. Prior to joining industry, Michael conducted basic neuroendocrine research, both as a fellow at Tulane University School of Medicine and as a staff researcher at the National Institutes of Health. In addition to his role as CSO for Alizé, Michael heads the scientific advisory board for Tiburio, and is a member of the Expert List Committee of the World Anti-Doping Association (WADA).

Patrick Loustau
Patrick Loustau, M.S., M.A.

Chief Business Officer

Patrick Loustau, M.S., M.A.

Chief Business Officer

Patrick Loustau has over 25 years of global experience in developing and managing biotech and pharmaceutical companies. Prior to joining Amolyt Pharma, from 2017-2019, Patrick was the chief executive officer of Zumbro Discovery, Inc., a clinical stage biotechnology company. From 2014-2016, he was the president of Zafgen, Inc., a Boston based biotechnology company focused on rare metabolic disease indications. Patrick was the senior vice president of global commercialization, cardiovascular and metabolics for Bristol-Myers Squibb from 2010-2014 and worked for 14 years for Novo Nordisk where he had several roles of increasing responsibility, most recently as senior vice president global marketing and medical affairs. Patrick attended The General Manager Program, Harvard Business School and holds a M.A. in human resources/marketing, M.S. in psychology and a B.A. in physiology.

Soraya Allas
Soraya Allas, M.D., PH.D.

VP, Clinical Development and Regulatory Affairs

Soraya Allas, M.D., PH.D.

VP Clinical Development and Regulatory Affairs

Soraya Allas has a broad drug development background and extensive experience in strategic and operational roles in the biotech industry. Prior to joining Amolyt Pharma, she was vice president, clinical development for Millendo Therapeutics where she led the pivotal clinical development program of the unacylated ghrelin analog, livoletide, in Prader-Willi syndrome (PWS). From 2010-2017, Soraya was medical director for Alizé Pharma where she led development and regulatory activities of all drug candidates, in particular livoletide from selection of lead through Phase 2a and Asparec®, a recombinant asparaginase. Prior to Alizé Pharma, she held leadership roles of increasing responsibilities in clinical development for endocrine and metabolic diseases at Theratechnologies that led to the approval of the growth hormone-releasing hormone analog, Egrifta®, for HIV-lipodystrophy. Soraya holds an M.D. from the University of Algiers and a Ph.D. in biomedical sciences from the University of Montreal.

Delphine Martinez
Delphine Martinez

General Counsel

Delphine Martinez

General Counsel

Prior to joining Amolyt Pharma, Delphine Martinez was the head of legal affairs for ERYTECH, a clinical stage biopharmaceutical company developing innovative therapies for rare forms of cancer and orphan diseases. Over her 13-year tenure at ERYTECH, she had the opportunity to deal with a wide range of legal issues varying from contracts to intellectual property, corporate law and human resources. Delphine contributed to all the development phases of the company from the establishment and the administration of its U.S. subsidiary to its listing on stock exchange markets, both on the Euronext and Nasdaq. She began her career within the legal department of Opi (now part of EUSA Pharma). Delphine holds a master's degree in international business law from the Jean Moulin University in Lyon and an MBA from I.A.E. Lyon School of Management.

Thomas Delale, Ph.D.
Thomas Delale, Ph.D.

VP, Portfolio Management

Thomas Delale Ph.D.

VP, Portfolio Management

Thomas Delale is a biopharmaceutical professional with over 18 years of experience that spans from peptide drug discovery to late clinical stage development and corporate/business development. He has actively supported the creation of Amolyt Pharma as program and corporate development lead. Thomas was most recently director, business development at Millendo Therapeutics (MLND). From 2010-2017, Thomas was the innovation manager for Alizé Pharma (acquired by Millendo Therapeutics) where he spearheaded livoletide (AZP-531) from discovery through Phase 2b/3 and supported business development and M&A activities. Prior to Alizé Pharma, he worked for the French Public Bank of Investment (Bpifrance). Thomas began his career as a scientist at the Schering-Plough Research Institute (now part of Merck & Co). Thomas holds a Ph.D. in immunology from the University of Lyon and a M.S. from the Ecole Normale Supérieure de Lyon.

David Duracher, Ph.D.

VP, Chemistry Manufacturing and Control

David Duracher, Ph.D.

VP, Chemistry Manufacturing and Control

David Duracher has over 18 years of global experience in parenteral drug development and drug delivery of peptides and proteins. Prior to joining Amolyt, he was Director of pharmaceutical development at Adocia where he led several project from discovery to Phase III covering CMC activities, formulation development, device project and managing outsourced manufacturing activities for the company on drug substance, drug product, devices and supply chain. David has a strong experience working with CMO/CRO and developing product with top pharmaceutical or biotechnologies companies in Europe, US, India and China. Prior to joining Adocia, he was working as a research and development formulation scientist at Flamel (now Avadel) on platform technologies and project for protein and peptide drug delivery. David holds a Ph.D. in chemistry and material science from University of Lyon and he completed his training by doing a post-doc at Sydney University.

Bénédicte Gagnere
Bénédicte Gagnere, M.S.

Head of Finance

Bénédicte Gagnere, M.S.

Head of Finance

Benedicte Gagnere has over 20 years experience in leading financial planning, control & accounting functions and reporting on all international operations. Prior to joining Amolyt Pharma, Benedicte was CFO of Navya an high tech company leader in self-driving solutions, where she helped the company scale and she partnered with founders to raise debt & equity capital. And she contributed to the company listing on EURONEXT stock exchange. Prior to that, Benedicte headed A+A Research Finance function. Benedicte spent the first decade of her career working in London for Fortune 500 companies such as General Electric. She holds a Master degree in Accounting and Finance, graduating from IAE Grenoble in 1996. She further enhanced her knowledge through completing in 1998 a professional accountancy qualification : DSCG.

Board OF DIRECTORS
Pierre Legault

Chairman of the Board of Directors

Pierre Legault, MBA, CPA

Chairman of the Board of Directors

In addition to serving as Amolyt Pharma’s chairman of the board, Mr. Legault also serves as the chairman of Artios Pharma, Bicycle Therapeutics and Poxel Pharma. He is lead director of Urovant Sciences and board director of Syndax Pharmaceuticals and has acted as a board director for more than 15 additional biopharmaceutical and pharmaceutical companies. Mr. Legault was the chief executive officer of Prosidion and served as the chief financial officer and treasurer of OSI Pharmaceuticals. Mr. Legault also worked as the chief executive officer of Eckerd Pharmacy and other companies. Previously, he held various global roles such as president and chief financial officers at legacy companies of Sanofi group. Mr. Legault earned his MBA in marketing from McGill University, his bachelor’s degree from HEC University of Montreal and also studied at Harvard Business School.

James Hindman

Chair of the Audit and Compensation Committees

James Hindman

Chair of the Audit and Compensation Committees

Mr. Hindman served for more than three decades in financial roles of increasing responsibility at Allergan, where he was instrumental in supporting that company’s development, which ultimately led to Actavis’ acquisition of Allergan in 2015. During his 30-plus year tenure at Allergan, Mr. Hindman held various senior leadership positions, including executive vice president of finance and business development and chief financial officer, as well as senior vice president, finance and controller. Additionally, he served as president of the Allergan Foundation from 2009-2015. Mr. Hindman earned his MBA from Pepperdine University and his B.S. in accounting from Loyola Marymount University. He currently serves as director of Accuray Incorporated and Aatru Medical, Inc. and is a member of the Loyola Marymount University Board of Regents.

Elisabeth Svanberg

Independent Director

Elisabeth Svanberg

Independent Director

Dr. Svanberg has extensive experience in the development of novel treatments for a range of endocrine, metabolic and other high-need diseases. She currently serves as chief development officer at Ixaltis SA, a specialty pharmaceutical company developing proprietary therapeutics to treat genitourinary disorders with unmet medical need. Prior to Ixaltis, she served as vice president, head of established products at Janssen Pharmaceuticals (a Johnson & Johnson Company) and as development leader for a first-in-class novel diabetes medicine and subsequently as head of medical affairs for the intercontinental region at Bristol Myers Squibb. Earlier in her career, Dr. Svanberg worked for Serono International in roles of increasing responsibility, initially in the field of metabolism. Dr. Svanberg serves as a non-executive director on the boards of Egetis AB (formerly PledPharma AB), Swedish Orphan Biovitrum AB, Galapagos and Pharnext SA. Dr. Svanberg received her M.D. and Ph.D. from the University of Gothenburg, Sweden and is a board-certified general surgeon and associate professor of surgery.

Felice Verduyn-van Weegen

Partner, LSP

Felice Verduyn-van Weegen, MBA

Partner, LSP

Felice Verduyn-van Weegen currently works as a Partner at LSP and serves on the board of several companies, including Vico Therapeutics, Evommune and Egle Therapeutics. Prior to joining LSP, she was a consultant at McKinsey & Company with a primary focus on healthcare. Before McKinsey, Ms. Verduyn-van Weegen was a neuroscientist and statistical geneticist, working with the prestigious complex traits genetics group at the Broad Institute and Harvard Medical School in Cambridge. She received her master’s degree in neuroscience from the VU University in Amsterdam, the Netherlands and her MBA from Columbia Business School in New York.

Naveed Siddiqi

Partner, Novo Ventures

Naveed Siddiqi, M.D.

Partner, Novo Ventures

Naveed Siddiqi, M.D., is a partner at Novo Ventures. He brings more than 20 years of experience in life science venture investments and investment banking. Most recently, he was partner at Andera Partners, a Paris based venture capital and growth equity firm with over €2 billion under management, focusing on life science investing. Prior to that, he worked for Nomura Phase4 Ventures, Nomura International, EFG Corporate Finance, KPMG and as a medical doctor in the UK’s National Health Service. Dr. Siddiqi has served on several life science company boards in both Europe and the U.S. Dr. Siddiqi obtained his M.D. from Guy’s and St. Thomas’s Hospital Medical School (now King’s College London). Later, he also qualified as a chartered accountant from the Institute of Chartered Accountants, England & Wales.

Thierry Laugel

Managing Partner, Kurma Partners

Thierry Laugel, PharmD, Ph.D., MBA

Co-Founder and Managing Partner, Kurma Partners

Thierry Laugel co-founded Kurma Partners in 2009 and currently serves as the managing partner. Additionally, he is a board member of Amolyt Pharma, Ermium, Horama, Minoryx, Blink Biomedical, Talix, Meiogenix and Pathoquest. Mr. Laugel started his career as R&D project manager for Laboratoires Fournier in Tokyo. Later, he joined Flamel Technologies, just after its successful listing on Nasdaq, and managed the development-stage portfolio of the company. He then moved to investments at Caisse des Dépôts (CDC) and then at AGF Private Equity (Allianz Group) in 2005. Mr. Laugel has led investments in more than 25 companies including Actelion, Arpida, Targacept, Adocia and Erytech. He earned his PharmD from Strasbourg University, Ph.D. from Paris Sud University and MBA from Institut Eurpéen d'Administration des Affaires (INSEAD).

Raphaël Wisniewski

Partner, Andrea Partners

Raphaël Wisniewski

Partner, Andrea Partners

Raphaël joined Andera Partners in 2001. Since joining Andera he has worked on numerous investments, M&As and IPOs. Raphaël has in depth experience in all types of transactions gained both in banking and in Venture Capital. He sits on the boards of ReViral, Grey Wolf Therapeutics, Enyo Pharma, Artios Pharma, AM Pharma, Exciva and Amolyt Pharma.

Raphaël began his career in London, where he spent seven years in the healthcare and investment banking industries. He was first part of the finance department of Générale de Santé International in London, the largest private hospitals group in the UK, where he held treasury and investment analysis functions. He subsequently worked in the healthcare groups of the Investment Banking divisions of Salomon Smith Barney (1996-1999) and Goldman Sachs (1999-2001). During his years in investment banking, Raphaël participated in many M&A and capital raising deals within pharmaceuticals, medical devices, biotechnology and services companies.

Raphaël graduated from the French business school HEC in 1993 and received a Master’s in Applied Economics from Institut d’Etudes Politiques in 1994.

Stefan Larson, Ph.D.

Partner, Sectoral Asset Management

Stefan Larson, Ph.D.

Partner, Sectoral Asset Management

Stefan is a Partner at Sectoral Asset Management, responsible for leading biotechnology private equity investments. He is also a member of the firm’s Management Committee. He serves as a director on the boards of Pipeline Therapeutics, Prilenia Therapeutics, Turnstone Biologics, and Amolyt Pharma.

Stefan graduated in 1997 from McGill University with a B.Sc. in Biology, and in 1999 from University of Toronto with an M.Sc. in Molecular and Medical Genetics. He completed his Ph.D. in Biophysics at Stanford University in 2004.

Prior to joining Sectoral, he was an Entrepreneur-in-Residence and later Venture Partner with Versant Ventures, where he led the establishment of their Toronto-based Discovery Engine and was the founding CEO of Northern Biologics. He was also a cofounder of two medical device companies: Perimeter Medical Imaging, and Tornado Spectral Systems. He began his career at McKinsey & Company in San Francisco and Toronto.

Thierry Abribat

CEO, Amolyt Pharma

Investors

Since its inception through series B financing, Amolyt Pharma, has raised 105 M€ (~$120 M) from a strong international syndicate of investors.

LSP
Novo Holdings
Kurma Partners
Andrea Logo
Mass General Brigham ventures
Pontifax
OrbiMed
bpifrance
Sectoral Asset Management
ATEM Capital Logo
SofiMAC
Turenne
sham partageons plus
initiative OCTALFA
Kreaxi
CA
Scientific and Medical Advisors
David Clemmons
David Clemmons, M.D.

University of North Carolina

Pierre Legault, MBA, CPA

Chairman of the Board Directors, Amolyt Pharma

In addition to serving as Amolyt Pharma’s chairman of the board, Mr. Legault also serves as the chairman of Artios Pharma, Bicycle Therapeutics and Poxel Pharma. He is lead director of Urovant Sciences and board director of Syndax Pharmaceuticals and has acted as a board director for more than fifteen additional biopharmaceutical and pharmaceutical companies. Mr. Legault was the chief executive officer of Prosidion and served as the chief financial officer and treasurer of OSI Pharmaceuticals. Mr. Legault also worked as the chief executive officer of Eckerd Pharmacy and other companies. Prior, he held various global roles such as president and chief financial officers at legacy companies of Sanofi group. Mr. Legault earned his MBA in marketing from McGill University, his bachelor’s degree from HEC University of Montreal and also studied at Harvard Business School.

Aart Jan (AJ) Van Der Lely, M.D., Ph.D.
Aart Jan (AJ) van der Lely, M.D., Ph.D.

Erasmus University Medical Center

Felice Verduyn-van Weegen, MBA

Investment Manager, LSP

Felice Verduyn-van Weegen currently works as an investment manager at LSP and serves on the board of several companies, including AM-Pharma, Vico Therapeutics, Pharvaris and Oxthera. Prior to joining LSP, she was a consultant at McKinsey & Company with a primary focus on healthcare. Before McKinsey, Ms. Verduyn-van Weegen was a neuroscientist and statistical geneticist, working with the prestigious complex traits genetics group at the Broad Institute and Harvard Medical School in Cambridge. She received her master’s degree in neuroscience from the VU University in Amsterdam, the Netherlands and her MBA from Columbia Business School in New York.

AZP-3601: Clinical Advisory Board
JOHN BILEZIKIAN
John Bilezikian, M.D.

College of Physicians & Surgeons, Columbia University

JOHN P. BILEZIKIAN, M.D., PH.D.(hon)

College of Physicians & Surgeons, Columbia University

Dr. Bilezikian, the Dorothy L. and Daniel H. Silberberg Professor of Medicine and Professor of Pharmacology at the College of Physicians & Surgeons, Columbia University is Vice Chair of the Department of Medicine for International Education and Research and Chief, Emeritus, of the Division of Endocrinology. He is Director, Emeritus, of the Metabolic Bone Diseases Program at Columbia University Medical Center. Dr. Bilezikian received his undergraduate training at Harvard College and his medical training at the College of Physicians & Surgeons. He completed four years of house staff training (internship, residency and Chief Residency) on the Medical Service at Columbia Presbyterian Medical Center. Dr. Bilezikian received his training in Metabolic Bone Diseases and in Endocrinology at the National Institutes of Health in the Mineral Metabolism Branch under the tutelage of Dr. Gerald Aurbach. He belongs to a number of professional societies including the American Society of Bone and Mineral Research, of which he served as President (ASBMR), 1995-1996 and the International Society of Clinical Densitometry (ISCD), of which he served as President, 1999-2001. He is a member of the Endocrine Society, the American Federation for Clinical Research, the American Society for Clinical Investigation, the Association of American Physicians, the American Association of Clinical Endocrinologists, the American Society for Pharmacology and Experimental Therapeutics, and the American College of Endocrinology that has designated him Master. He served on the Board of Governors of the International Osteoporosis Foundation (1999-2015) and is a current member of its Committee of Scientific Advisors. He is Chair of the Endocrine Fellows Foundation. He served as Editor-in-Chief of the Journal of Clinical Endocrinology and Metabolism and as Senior Associate Editor of the Journal of Bone and Mineral Research. He is Executive Advisory Editor of Bone Research. His books include Editor-in-Chief of The Parathyroids [1994, 2001, 2015], and co-editor of The Aging Skeleton (1999), Dynamics of Bone and Cartilage Metabolism (1999, 2006), Principles of Bone Biology (1996, 2002, 2008, 2020) and Osteoporosis in Men (2010). He is Editor-in-Chief of the Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism (2019). He has been on numerous panels, including serving as Chair of the NIH Consensus Development Panel on Optimal Calcium Intake (1994), Co-chair of the last three International Workshops on Primary Hyperparathyroidism (2002, 2008, 2013) and of the first International Workshops on Hypoparathyroidism (2015) and Controversies in Vitamin D (2017, 2018, 2019). Dr. Bilezikian's major research interests are related to the clinical investigation of metabolic bone diseases, particularly primary hyperparathyroidism, hypoparathyroidism and osteoporosis, His studies of parathyroid hormone in these disorders with regard to etiology, clinical manifestations, pathophysiology, mechanisms of skeletal involvement, and therapy are known throughout the world as landmark contributions to our knowledge of these disorders. He has been continuously funded by the NIH since 1974. Over 850 publications speak to these active original investigative initiatives as well as his authorship of many reference sources of endocrinology and metabolic bone diseases.

Dr. Bilezikian is the recipient of the Distinguished Physician Award of the Endocrine Society, the Frederic C. Bartter Award of the ASBMR for Excellence in Clinical Research, and the First Annual Global Leadership Award of the ISCD. In 2009, he received the Gideon A. Rodan Excellence in Mentorship Award from the ASBMR. He received the Laureate Distinguished Educator Award of the Endocrine Society in 2014. In 2014, he was made honorary member of the Brazilian Society of Endocrinology and Metabolism and the Association of Brazilian Orthopedic Osteologists. In 2015, he received the Oscar Gluck Humanitarian Award of the ISCD and the Inaugural Global Educator of the Year Award from McMaster University in Canada. In 2017, he was named Honorary Member of the Russian Osteoporosis Association. Dr. Bilezikian has received Lifetime Achievement and Recognition Awards of the California and Boston Armenian American Medical Societies and the Armenian American Health Professionals Organization (AAHPO). In 2017, he received the Doctor Honoris Causa Award from the Carol Davila School of Medicine in Bucharest, Romania and from the University of Pisa, in Pisa, Italy. He received the Distinguished Physician Award of the American Association of Clinical Endocrinologists in 2018. He received the Ellis Island Congressional Medal of Honor from the United States Government in 2018. Also, in 2018 he received a Parliamentary Medal of Honor from the Government of Armenia for distinguished service and a similar honor from the Government of Brazil. In 2019, he received the Gold Medal for Outstanding Achievements in Medical Research, the highest honor that Columbia University’s College of Physicians and Surgeons bestows on its graduates. In 2020, Dr. Bilezikian received the ASBMR William F. Neuman Award for highest scientific achievement.

MARIA LUISA BRANDI
Maria Luisa Brandi, M.D.

University of Florence

Maria Luisa Brandi, M.D.

University of Florence

Maria Luisa Brandi MD is Full Professor of Endocrinology at the University of Florence, Medical School, Florence, Italy. She was trained as a medical doctor at the University of Florence and went on to earn her specialist degree in endocrinology at the University of Florence Hospital. She was a Visiting Scientist in Metabolic Diseases, Metabolic Diseases Branch, NIH, Bethesda, Maryland, and additionally earned a Ph.D. in Cell Biology at the University of Rome. Since 1990 she has been Director, Regional Center on Hereditary Endocrine Tumors, University Hospital of Florence. From 1998 she has been Director of the Clinical Unit on Metabolic Bone Disorders, University Hospital of Florence.

Additional current and past positions include: Delegate, Italy/USA Academic Interactions, Florence University, 2000-2003; Director of the University Master on Metabolic Bone Disease: From the Gene to the Cure, University of Florence, 2004-to present; Scientific Director, DeGene Spin-off, University of Florence, 2005-2009; Member of the Commission for Osteoporosis of the Italian Ministry of Health 2009 – 2011. She is currently President, Fondazione Italiana Ricerca sulle Malattie dell’Osso (F.I.R.M.O),Consultant for the Tuscany Region on Osteoporosis and well as Scientific Attaché for the City of Florence.

Prof. Brandi has won many honors and awards, including: Roussel Italia Award, 1988; The European Foundation Award, 1989; Schering Award, Italian Endocrine Society, 1990; The Sandoz Foundation for Gerontological Research Award, 1991; Helena Rubinstein Award “Women in Science”, 1998; Italian Endocrine Society Senior Award, 2003; AILA Award, 2004, Pierre Delmas IOF/ESCEO Prize 2013.

She has been or is on the editorial boards of major scientific journals and is currently Editor-in-Chief of Clinical Cases in Bone and Mineral Metabolism. Prof. Brandi has published more than 600 papers in peer-reviewed journals and 250 chapters and books. Her current research focus is on genetics and clinical aspects of osteoporosis; pathogenesis of parathyroid disorders; multiple endocrine neoplasia; genetics of Paget’s Disease; bone cell biology; epidemiology of osteoporosis; and inherited bone disorders.

Among her many professional memberships, Prof. Brandi is Past President of S.I.O.M.M.M.S. (Italian Society of Osteoporosis and Metabolic Bone Diseases), General Secretary of ESCEO, and Executive Director of the OrtoMed Society. In her role as President of F.I.R.M.O, Professor Brandi has shown great commitment to public education and outreach in Italy, also on behalf of IOF and World Osteoporosis Day.

BART L. CLARKE, M.D​
Bart L. Clarke, M.D

Mayo Clinic

Bart L. Clarke, M.D.

Mayo Clinic

Bart L. Clarke, M.D. is Consultant and a member of the Metabolic Bone Disease Core Group in the Division of Endocrinology, Diabetes, Metabolism, and Nutrition at the Mayo Clinic, and Professor of Medicine in the Mayo Clinic College of Medicine. His current clinical research interests include parathyroid disorders, rare bone diseases, postmenopausal osteoporosis, new anabolic therapies for osteoporosis, glucocorticoid- and transplantation-induced osteoporosis, and tumor-induced osteomalacia. He is Past-President and a former Council member of the American Society for Bone and Mineral Research, and a member of the Endocrine Society, American Association of Clinical Endocrinologists, and the American College of Physicians. He is on the editorial board for Bone and Osteoporosis International, served on the FDA Reproductive Health Drug Advisory Board, and is a current Chair of the Mayo Clinic Institutional Review Board.

Aliya Khan, M.D.
Aliya Khan, M.D.

McMaster University

Aliya Khan, M.D., FRCPC, FACP, FACE

McMaster University

Aliya Khan is a Clinical Professor of Medicine, Divisions of Endocrinology and Metabolism and Geriatrics at McMaster University . She is the Director of the Calcium Disorders Clinic as well as the Fellowship in Metabolic Bone Disease at McMaster University. She graduated from the University of Ottawa Medical School with Honors and trained in Internal Medicine, Geriatrics and Endocrinology at the University of Toronto and also completed a research fellowship in Metabolic Bone Disease at the University of Toronto.

She has published over 200 scientific papers on osteoporosis and parathyroid disease as well as numerous book chapters and books on parathyroid disease. Dr Khan is the Chair of the Rapid Response Committee of Osteoporosis Canada ;a Scientific Advisor of the International Osteoporosis Foundation and the Canadian Ambassador for the American Society of Bone and Mineral Research .

Dr. Khan has been recognized by numerous national and international awards including the Queen’s Diamond Jubilee Medal for 2012 for excellence in clinical care, research and teaching as well as the International Hypoparathyroidism Award for 2014 and the International Osteoporosis Foundation award for publishing excellence in 2017. In 2019 she was recognized as being in the top 0.1% of the world experts in hyperparathyroidism by Expertscape.

Michael Mannstadt
Michael Mannstadt, M.D.

Massachusetts General Hospital and Harvard Medical School

Michael Mannstadt, M.D.

Massachusetts General Hospital and Harvard Medical School

Michael Mannstadt, MD is Chief of the Endocrine Unit at the Massachusetts General Hospital and Associate Professor in Medicine at Harvard Medical School. His clinical and research interests focus on diseases bone and mineral metabolism. He is particularly interested in hypo- and hyperparathyroidism, and his research spans the basic, translational, and clinical realms of these diseases.

Lars Rejnmark, M.D.
Lars Rejnmark, M.D.

Aarhus University

Lars Rejnmark, M.D.

Aarhus University

Lars Rejnmark, MD, Ph.D., DMSc, is a professor of endocrinology at Aarhus University and serves as a consultant at Department of Endocrinology and Internal Medicine, Aarhus University Hospital. He has published more than 250 papers in peer-reviewed journals focusing on calcium homeostasis, the vitamin D-parathyroid axis, and bone metabolism. Rejnmark has participated in drafting the European Society of Endocrinology clinical guideline on treatment of chronic hypoparathyroidism in adults as well as drafting national guidelines on primary hyperparathyroidism. Rejnmark is currently serving as a co-chair of the main thematic groups on calcium-phosphate disorders in the European reference network on rare endocrine diseases (Endo-ERN), as well as a clinical focus area lead by the European Society of Endocrinology on bone and calcium disorders.

Scroll to Top